申请人:DIGNITY HEALTH
公开号:US11065244B2
公开(公告)日:2021-07-20
Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic β-cell KATP channels, and can be developed to a novel drugs for treating disease and/or conditions such as diabetes and Parkinson's disease.
四氢小檗碱(THB)是从中草药 "伏苓 "中分离出来的,具有多种药理作用,但其作用机制尚不清楚或完全未知。本文介绍了使用四氢小檗碱(THB)、THB 类似物或衍生物、四氢小檗碱(THPB)的新方法。四氢小檗碱(THB)和类似物(如 l-epholidine(l-SPD))能有效阻断中脑多巴胺神经元上原生表达的功能性 KATP 通道。此外,四氢小檗碱还能阻断胰腺β细胞的KATP通道,可开发成治疗糖尿病和帕金森病等疾病和/或病症的新型药物。